Mira Pharmaceuticals Reports $1.2 Million Net Loss in Q2 2026, Focuses on R&D

Mira Pharmaceuticals, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of approximately $1.2 million, a decrease from a loss of $1.5 million in the same period of 2025. For the six months ended June 30, 2026, the company recorded a net loss of $2.4 million, compared to a loss of $3.3 million for the first half of 2025. The company has not generated any revenue during these periods, maintaining a focus on research and development for its product candidates, which include Ketamir-2, MIRA-55, and SKNY-1.

Total operating costs for the second quarter of 2026 were approximately $1.2 million, down from $1.5 million in the prior year, primarily due to a significant reduction in general and administrative expenses, which fell from $1.05 million to $450,330. This decrease was attributed to lower stock-based compensation and reduced payroll-related expenses. Conversely, research and development expenses increased to $705,789 from $496,197, reflecting heightened activity in advancing the company’s clinical trials and preclinical studies.

Mira Pharmaceuticals has made strategic moves to enhance its product pipeline, including the acquisition of SKNY Pharmaceuticals in September 2025, which has allowed the company to expand its focus into metabolic indications. The company is advancing its lead candidate, Ketamir-2, toward a Phase 2a clinical trial for chemotherapy-induced peripheral neuropathy, with plans to initiate the trial in early 2027, pending regulatory approvals. The company also reported a loss of $179,126 from its equity method investment in Telomir Pharmaceuticals, reflecting its share of losses from this related party.

As of June 30, 2026, Mira Pharmaceuticals had cash and cash equivalents of approximately $3.6 million, a decrease from $6.3 million at the end of 2025. The company used about $2.4 million in cash for operating activities during the first half of 2026, consistent with the previous year. The company has indicated that it may need to secure additional funding to support ongoing operations and clinical trials, as it currently lacks sufficient cash to sustain operations for the next 12 months. Management has expressed the need to explore various financing options, including public and private equity offerings, to alleviate concerns regarding its ability to continue as a going concern.